Category » News
Sofinnova Digital Medicine will back entrepreneurs innovating at the cutting edge of technology and biology and help them scale and become global leaders. Like all the funds on Sofinnova’s platform of strategies, Sofinnova Digital Medicine will focus on developing the most promising innovations that address systemic challenges in healthcare and can profoundly improve the lives of patients worldwide.
GoJoe is a hybrid consumer and B2B app that enables workplaces and brands to connect and engage their people. It combines wearables, content, and team-based challenges and experiences to socialize everyday solo exercise for the masses of “ordinary joes” and help people stick to their fitness and well-being journeys. The company collaborated with Stanford University on psychology, data, and gamification to build the app, which is used by brands including PwC, PayPal, Experian, and Amazon.
The Finnish medical imaging company aims to speed up the cancer treatment planning process while still delivering high-quality care. Its approach calls for AI-powered automatic segmentation tooling, which lets it streamline the all-important radiotherapy treatment planning workflow. Compared to manual treatment planning, which often requires two to three weeks of anxious waiting before radiotherapy treatment planning starts, MVision’s automation enables same-day treatment.
AERA Health’s hybrid model brings data-driven P4 medicine to consumers via existing healthcare infrastructure. P4 medicine focuses on future-oriented health plans, using data to foresee patient issues (predictive), acting to prevent rather than cure diseases (preventive), making tailored diagnoses and therapies (personalized), and including patients in decisions (participatory).
Founded out of Berlin in 2017, Medwing targets the healthcare industry in Germany and the U.K. with a platform designed to match hospitals and clinics with nurses and elderly caregivers, though it also caters to pharmacists, midwives, doctors and similar professionals. The platform is currently available in Germany and the U.K., where it claims some 5,500 registered medical employers and 500,000 healthcare professionals, who can access an entirely digital workflow spanning job search, contracts, signatures and timesheets.
The level of European investment has therefore continued to grow in 2022, albeit in a more measured way than between 2020 and 2021. 301 deals were closed, representing a 22% YoY increase in total financing. There are now 1000+ companies active in digital health across Europe today. In contrast, the level of investment in the US in digital health has dropped significantly, while Europe has been more stable in 2022.
The London-based healthtech startup will use the funds (Series B) to further expand its network of therapists, partners, and members across the UK and Continental Europe. Octopus Ventures led the round with the participation of existing investors Omers, Mantaray, and Oxford Capital.
Global Digital Therapeutics market is valued at $3.16 Billion in 2021 and is projected to attain a value of $14.52 Billion by 2028 at a CAGR of 28.1% during the forecast period, 2022–2028. The general public has become more conscious of the continuously shifting digital scene. Furthermore, the market is fueled by rising chronic disease prevalence and rapid technology improvements. End-user awareness is predicted to rise as a result of the use of digital devices and solutions, propelling the industry forward. Consumer attitudes toward digital health are predicted to continue to alter, as will their demand for accessible, personalized, and engaging medical solutions.
Varjo, machineMD team up to develop VR-based eye-tracking solution for the diagnosis of brain disorders
The two parties will work on developing Neos, a diagnostic device for the early diagnosis of brain disorders. Neos will be integrated with the Varjo Aero headset to enable a complete, standardized, and instrument-based neuro-ophthalmologic examination using the headset’s built-in VR-based eye-tracking solution. Varjo and machineMD stated that the development of Neos is advancing rapidly, with ongoing research studies at The University Hospital of Bern and several other clinics currently underway.
Now in its seventh consecutive year, the NHS-delivered programme, has supported 143 of the biggest and most effective digital innovations now being used by the NHS and social care, and many scaling globally. Examples include Huma, DrDoctor, Peppy Health, eConsult, Echo, AccuRx and HN. Over 600 additional contracts have been signed by companies during Accelerator support and the programme was also named Accelerator of the Year at the UKBAA Angel Investment Awards 2022.
Under the deal, Dawn Health will develop a platform that empowers patients and their care teams to make better and faster treatment decisions. By combining a patient mobile app focused on high engagement and exceptional UX with innovative elements like symptom tracking, novel (digital) biomarkers, clinical decision support services, virtual clinic capabilities and other relevant services as they become available – the platform will be tailored very specifically to the needs and demands of each separate disease in scope.
A hospital in Spain is launching a study to test the efficacy, tolerability, and acceptance of a drug produced for children using a 3D printer. The study results from collaboration between the Pharmacy Service at Vall d’Hebron University Hospital, the University of Santiago de Compostela, and the company FabRx. The 3D printer used for the study produces medicines in semi-solid and chewable forms, which are personalized to each child based on their weight and clinical characteristics.
Called Izar, it is an FDA-listed and CE-marked smart peripheral for patients with impairment in hand motor function. Izar is designed to fill a critical gap in neurological care today and aims to be the most effective hand dexterity and strength treatment in a wide range of neurological conditions. This proprietary peripheral is part of a comprehensive omnisite approach to the treatment and maintenance of neurological diseases, including Stroke, Parkinson’s disease, Alzheimer’s disease, and Traumatic Brain Injury (TBI), among others.
The new skin temperature-based cycle tracking capabilities will be available through the Samsung Health app on the Galaxy Watch5 and Watch5 Pro within the second quarter in 32 markets, which includes Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Korea, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, the U.K. and the U.S.
EPFL researchers have combined low-power chip design, machine learning algorithms, and soft implantable electrodes to produce NeuralTree, a closed-loop neuromodulation system-on-chip that can detect and alleviate symptoms of various neurological disorders.
Starting with the UK, the company now brings together Headspace’s world-class meditation and mindfulness offering with on-demand coaching, therapy and EAP services to provide a single mental health solution that reduces complexity, administrative burden and cost for employers. Headspace Health plans to extend these services into additional markets throughout 2023.
In this cohort study of 11 801 patients with OUD with commercial insurance or Medicare Advantage coverage, there were no significant differences in visit frequency, initiation of medications for OUD, or OUD-related adverse outcomes between those who were treated by clinicians with high vs low telemedicine use across the prepandemic and pandemic periods.
A new report by EIT Health InnoStars explores the state of digital therapeutics (DTx) and barriers in selected 6 EU countries. It also indicates 11 strategic recommendations for accelerating DTx in the EU.
This economic evaluation of cost savings from completed telehealth appointments included 11 688 patients younger than 65 years, with 25 496 telehealth visits at a National Cancer Institute–Designated Comprehensive Cancer Center from April 1, 2020, to June 30, 2021. According to cost models, the estimated mean total cost savings ranged from $147.4 to $186.1 per visit.